SCHEMBL5405183

SCHEMBL5405183

NCc1nccn2c(-c3ccc(F)cc3F)cnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 4/20 0.40
WDR77 Q9BQA1 4/20 0.40
HASPIN Q8TF76 2/20 0.38
KIT P10721 1/20 0.38
PIM1 P11309 1/20 0.38
FLT3 P36888 1/20 0.38
CDK7 P50613 1/20 0.38
KCNH2 Q12809 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
DPP4 P27487 1/20 0.38
KDM4A O75164 1/20 0.36
KDM5A P29375 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
MAP4K4 O95819 6/20 0.36
MAPK9 P45984 6/20 0.36
CSNK1D P48730 6/20 0.36
CSNK1A1 P48729 5/20 0.36
MINK1 Q8N4C8 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401149 0.84 CCNE2 (0.41) PRMT5WDR77FLT3GABRA1GABRG2
SCHEMBL5406212 0.78 PRMT5 (0.47) PRMT5WDR77GABRA1GABRG2GABRB3
SCHEMBL5405186 0.77 FLT3 (0.52) HASPINKITPIM1FLT3CDK7
SCHEMBL5412317 0.76 FLT3 (0.46) PRMT5WDR77HASPINFLT3SMN1; SMN2
SCHEMBL5399692 0.74 CCNE1 (0.38) PRMT5WDR77PIM1FLT3DPP4
SCHEMBL5403389 0.74 CCNE2 (0.41) PRMT5WDR77FLT3DPP4SMN1; SMN2
SCHEMBL5404980 0.73 MAPT (0.41) DPP4GABRA1GABRG2GABRB3GABRA3
SCHEMBL5618295 0.72 TTK (0.36) PRMT5WDR77SMN1; SMN2L3MBTL1
SCHEMBL5400802 0.72 PRMT5 (0.43) PRMT5WDR77SMN1; SMN2L3MBTL1
SCHEMBL5401418 0.71 KDM4E (0.43) PRMT5WDR77SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 US claimed
US-20040220189-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors SUGEN, INC. 2004-11-04 US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 US disclosed
US-7157460-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 US disclosed
US-20040220189-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors SUGEN, INC. 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 PRMT5 728/4885WDR77 2178/4885HASPIN 517/4885
US-20040220189-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors MAP3K8, MAP4K4, MAP3K2 PRMT5 1599/4885WDR77 3638/4885HASPIN 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.